An object of the present invention is to provide a novel ascochlorin derivative which activates adenosine monophosphate-activated protein kinase (AMPK), and is useful in the treatment or prevention of diseases or conditions that involve AMPK dysregulation. The present invention provides a compound presented by formula I, a pharmaceutically acceptable salt or a solvate thereof.

This invention is directed to, inter alia, compounds, methods, systems, and compositions for the maintenance, enhancement, and expansion of hematopoietic stem cells derived from one or more sources of CD34+ cells. Sources of CD34+ cells include bone marrow, cord blood, mobilized peripheral blood, and non-mobilized peripheral blood. Also provided herein are compounds of Formula I

##STR00001##

which are useful in maintaining, enhancing, and expanding of hematopoietic stem cells.

This invention is directed to, inter alia, compounds, methods, systems, and compositions for the maintenance, enhancement, and expansion of hematopoietic stem cells derived from one or more sources of CD34+ cells. Sources of CD34+ cells include bone marrow, cord blood, mobilized peripheral blood, and non-mobilized peripheral blood. Also provided herein are compounds of Formula I

##STR00001##

which are useful in maintaining, enhancing, and expanding of hematopoietic stem cells.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are substituted (4-hydroxylphenyl)cycloalkane compounds and there use as selective agonists of the estrogen receptor beta isoform (ER). The disclosed compounds may be formulated as pharmaceutical compositions and administered to treat diseases associated with ER activity, such as proliferative diseases and disorders and/or psychiatric diseases or disorders.

Disclosed are substituted (4-hydroxylphenyl)cycloalkane compounds and there use as selective agonists of the estrogen receptor beta isoform (ER). The disclosed compounds may be formulated as pharmaceutical compositions and administered to treat diseases associated with ER activity, such as proliferative diseases and disorders and/or psychiatric diseases or disorders.

Ammoximation reactor for cyclohexanone oxime production comprising: (a) a reactor vessel provided with a stirrer; (b) an internal filtering system; (c) an internal liquid ammonia evaporation coil; (d) an internal gaseous ammonia toroidal distributor; (e) an external cyclohexanone toroidal distributor; (f) an internal hydrogen peroxide toroidal distributor; (g) an internal cylindrical draft tube; (h) an external cooling jacket. Said ammoximation reactor allows to obtain a better mixing of the components of the ammoximation reaction and to maximize both the heat-transfer coefficients and the mass-transfer coefficients. Moreover, said ammoximation reactor allows to increase the packing time of the catalyst used in the ammoximation reaction on the filtering system (i.e. the plugging phenomena) so as to avoid the necessity of carrying out the backwashings with nitrogen. Moreover, said ammoximation reactor does not require external downstream separation units to separate the catalyst from the reaction mixture obtained from the ammoximation reaction.

Ammoximation reactor for cyclohexanone oxime production comprising: (a) a reactor vessel provided with a stirrer; (b) an internal filtering system; (c) an internal liquid ammonia evaporation coil; (d) an internal gaseous ammonia toroidal distributor; (e) an external cyclohexanone toroidal distributor; (f) an internal hydrogen peroxide toroidal distributor; (g) an internal cylindrical draft tube; (h) an external cooling jacket. Said ammoximation reactor allows to obtain a better mixing of the components of the ammoximation reaction and to maximize both the heat-transfer coefficients and the mass-transfer coefficients. Moreover, said ammoximation reactor allows to increase the packing time of the catalyst used in the ammoximation reaction on the filtering system (i.e. the plugging phenomena) so as to avoid the necessity of carrying out the backwashings with nitrogen. Moreover, said ammoximation reactor does not require external downstream separation units to separate the catalyst from the reaction mixture obtained from the ammoximation reaction.

The present disclosure relates to compositions and methods related to bicyclo[2.2.1]heptanamine-containing compounds and salts thereof.